RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
||Ayala Pharmaceuticals, Inc
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / email@example.com
You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the study drug), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study drug and how your body processes the drug. The study drug works by stopping a chemical pathway in the cells that allows desmoid tumors to grow. It is hoped that by stopping this pathway the study drug will stop desmoid tumor cells from growing and may cause them to shrink.
Gary Schwartz, MD
|Are you age 18 or older?
|Have you been diagnosed with a desmoid tumor?